Cancer seeding contributes to intestinal anastomotic dehiscence by Marek Stanczyk et al.
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
Stanczyk et al. World Journal of Surgical Oncology 2013, 11:302
http://www.wjso.com/content/11/1/302RESEARCH Open AccessCancer seeding contributes to intestinal
anastomotic dehiscence
Marek Stanczyk1,2,3*, Waldemar L Olszewski1, Magdalena Gewartowska1 and Marek Maruszynski2Abstract
Background: Surgical wounds in cancer patients have a relatively high dehiscence rate. Although colon cancer
resections are performed so as to include macroscopically non-involved tissues, some cancer cells can be present in
the line of transection. The local healing process may facilitate proliferation of these localized cancer cells and the
high cytokine concentration within the healing wound may also attract cancer cells from distant sites to migrate
into the wound area. The growing tumor cells may then stretch the wound, hampering its contraction process.
Methods: The aim of the study was to monitor and compare, using immunohistochemical methods, the healing
process of intestinal anastomosis in both normal rats and in rats with disseminated cancer (the CC531 colon cancer
model).
Results: There was a significantly higher rate of anastomotic dehiscence in the group of rats with disseminated
cancer, than in the group of normal rats. There were no significant differences between the two groups in the
levels of mononuclear wound infiltration or of formation of connective tissue or new vessels. All anastomotic
wounds in animals with disseminated cancer had abundant infiltrates of both migrating and proliferating cancer
cells.
Conclusions: We confirmed that the environment of a healing wound attracts cancer cells. Migration of cancer
cells to the wound and centrifugal cancer proliferation may adversely affect the healing process and cause wound
disruption.Background
The normal wound-healing process can be divided into
three stages: 1) inflammatory, 2) proliferative, and 3)
repair and remodeling. The inflammatory stage is initi-
ated by blood coagulation and platelet degranulation. In
response to released chemotactic factors, monocytes enter
the wound and mature into wound macrophages. Wound
macrophages phagocytose wound debris, and in conjunc-
tion with infiltrating lymphocytes, release growth factors,
which induce migration and proliferation of fibroblasts,
epithelial cells, and endothelial cells during the prolifera-
tive phase of healing. At the end of the proliferative phase,
fibroblasts produce collagen, elastin, proteoglycans, and
other extracellular matrix (ECM) components, resulting* Correspondence: stanczyk@poczta.onet.pl
1Deptartment of Human Epigenetics, Mossakowski Medical Research Centre,
Polish Academy of Science, Warsaw, Poland
2Department of General, Oncologic and Vascular Surgery, Military Institute of
Medicine, Warsaw, Poland
Full list of author information is available at the end of the article
© 2013 Stanczyk et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orin scar tissue formation [1,2]. Remodeling and repair of
scar tissue is controlled by action of metalloproteinases
secreted by fibroblasts and downregulated by production
of tissue inhibitor of matrix metalloproteinases (TIMPs).
A number of reports confirmed observations that inflam-
mation may be an important cofactor of tumorgenesis in
sites of chronic irritation, persistent infection, and previ-
ously wounded tissue [3,4]. Macrophages also play a role
in tumor growth in conjunction with lymphocytes, by
synthesizing and secreting epidermal growth factor (EGF),
basic fibroblast growth factor, and transforming growth
factor (TGF) α and β along with other chemokines re-
leased during wound healing and inflammation, including
tumor necrosis factor-α, interleukin 6, platelet-derived
growth factor (PDGF) and vascular endothelial growth
factor (VEGF) [5-9]. Tumor growth results in disruption
of the normal tissue architecture, and induces a wound-
healing response similar to that found in the normal heal-
ing wound. Because of these similarities, tumors are often
described as ‘wounds that do not heal’ [10,11]. There isl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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local or systemic inflammation worsens prognosis in
patients undergoing oncologic treatment. The delayed
wound healing is associated with increased rate of
systemic but not local recurrence after breast cancer
surgery [12]. The anastomotic leakage after colorectal
cancer surgery might enhance the incidence of local
recurrence, and contribute to worse prognosis [13-17].
Surgical wounds in cancer patients have a higher
dehiscence rate. Excision of tumor tissue is aimed at
removal of the bulk of the tumor mass. However, even if
tissue is transected at a large distance from the tumor
edge, it is possible that individual tumor cells may be
present in the presumed non-cancerous tissues. Presence
of cancer at the anastomotic margin contributes to anas-
tomotic leakage and ‘suture-line’ recurrence. This situ-
ation is rarely encountered in modern-day treatment, as
the principles of negative proximal and distal margins
are well appreciated, and the use of frozen section
control of resection margins (if close or doubtful) is
standard practice.
The local healing process may facilitate cancer cell
proliferation within the wound, and the high levels of
cytokines produced during the healing process may
attract cancer cells from distant tissues to migrate to
and proliferate within the wound [18]. These residual or
newly attracted tumor cells then become involved in the
wound-healing process [19].
The question arises as to how tumor cells react in all
three stages of normal tissue healing compared with the
local parenchyma and mesenchymal cells adjacent to the
wound. Tumor cells proliferate with a net mass increase,
whereas the neighboring normal tissue undergoes retrac-
tion and scar formation. It is therefore possible that the
growing tumor cells will stretch the wound, hampering
the process of wound contraction. The wound environ-
ment may accelerate tumor growth and subsequently
lead to wound dehiscence. In addition to clarifying the
clinical aspects of wounds containing tumor cells, stud-
ies of the kinetics of cellular events in such wounds
would give insight into the environmental, humoral, and
cellular factors stimulating tumor growth.
Two further questions then arise: does the healing
process in ‘cancer-contaminated’ tissue proceed in a
similar way as in the healthy tissue, and does the healing
process stimulate proliferation of individual tumor cells
present in the wound? Even though the mechanical
dissemination of cancer cells during surgery has been
discussed in the medical literature since the end of the
19th century, and was extensively studied in the 1960s,
the literature on the cellular events occurring in healing
cancer wounds is sparse and inconsistent [20-22]. A few
studies showed correlations between events occurring
during wound healing and the processes of cancerspread; however, they did not answer the basic issue of
the effect of the wound environment on tumor cell
growth. In order to address this issue, a comparison of
wound healing of normal and cancer-contaminated
tissues is required.
The aim of the current study was to compare, using
immunohistochemical methods, the healing of normal
intestinal anastomoses and anastomoses performed in rats




We used male Wistar AG (WAG) rats (250 to 300 g
body weight; 8 to 9 weeks old), bred and maintained in
our own facility. Rats were maintained in standard con-
ditions, and received rodent laboratory chow and water
ad libitum.
All experimental animals were treated in accordance
with the guidelines of the ethics commission of the
Polish Academy of Science.
CC531 cancer cells
CC531 is a moderately differentiated and weakly im-
munogenic adenocarcinoma of the colon which is in-
duced by 1,2-dimetylhydrazine and is syngenic to WAG/
Rij rats. CC531 cells (kindly provided by Dr P Kuppen,
Leiden University Medical Centre, the Netherlands) were
cultured in RPMI medium supplemented with 10% FCS,
penicillin, streptomycin, fungizon (all from Gibco, Breda,
the Netherlands) and ceftriaxone (Polpharma, Warsaw,
Poland). The cultures were maintained in plastic tissue
culture flasks, and incubated in 5% CO2 at 37°C in a
humidified incubator. Tumor cells were harvested from
sub-confluent cultures (80 to 90% confluence) by brief
(10 minutes) exposure to trypsin (Gibco) diluted 1:10 in
PBS without Ca2+ or Mg2+ (Gibco). Cells were suspended
in PBS without Ca2+ or Mg2+ supplemented with 10%
FCS, and centrifuged at 400 g for 10 minutes, then resus-
pended in serum-free PBS without Ca2+ or Mg2+, and
centrifuged as before. Cell viability was determined by the
Trypan blue exclusion method, and was always greater
than 90% [23,24].
Inoculation of CC531 cells
Rats (n = 20) were anesthetized with ether. A mid-line
incision 2 cm long was made in the abdominal wall. A
suspension of 2 × 106 CC531 cells in 0.5 ml 0.9% NaCl
was prepared for each animal, and injected into the portal
vein. Abdominal wounds were sutured. Liver and periton-
eal metastatic-type tumors developed 4 to 6 weeks after
CC531 inoculation. Out of the 20 rats, 4 did not develop
any metastasis, 2 had individual tumor foci in the liver,
and 2 had advanced cancer with peritonitis. These 8 out
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excluded from the study and euthanized by decapitation.
For the study, we used a homogeneous group of 12
rats with at least four tumor metastases 4 mm in size to
the liver, and a few individual peritoneal tumors but no
peritonitis. Tumor stage was assessed during the intes-
tinal resection.
Intestinal anastomoses
We performed excisions of a short segment (approxi-
mately 10 mm long) of the distal intestine with subse-
quent end-to-end restoration of intestinal continuity in
two groups of rats. Group 1 consisted of 12 rats with
CC531 colon cancer metastatic tumors, while group 2
(the control group) consisted of 12 normal healthy rats.
Bromdeoxyuridine administration
Six rats were randomly chosen from both the cancer and
control groups. Intraperitoneal injection of bromodeox-
yuridine (BrdU) 10 mg was administered daily to each rat
on days from 1 to 3 during the observation period.
Immunohistochemistry of intestinal wounds
On days 3, 7 and 14, samples of anastomotic wounds
were taken. Samples were cut on a cryostat into sections
5 μm thick, which were mounted onto polylysine-
treated slides. Cryosections were fixed in alcohol for
hematoxylin and eosin and for trichrome staining. For
immunohistochemical staining, cryosections were fixed
in cold acetone for 10 minutes, then air-dried, and incu-
bated with goat serum (diluted 1:1 in Tris-buffered
saline) for 20 minutes, followed by incubation for 30
minutes with primary mouse monoclonal antibodies
against OX6 (for major histocompatibility complex class
II; MHC II), ED1 (rat monocytes and macrophages),
W3/13 (leucocytes), HIS52 (vascular endothelium), and
BrdU (proliferating cells) (all from Serotec, Oxford, UK)
and anti-CC531 (kindly provided by Dr P Kuppen as be-
fore). The specificity of immunostaining was confirmed
by incubation of some sections without primary antibody.
The antibody reactions were visualized using the LSAB-2
Alkaline Phosphatase Kit (Dako, Glostrup, Danmark), in
accordance with the manufacturer’s instructions.
The cell subpopulations infiltrating the wound site
were counted in five microscopic areas (×400 magnifica-
tion) of intestinal wounds of normal and cancer-bearing
rats using light microscopy with microimage software
(Olympus, Japan).
Blood vessels in the wound were counted in five
microscopic areas (×200 magnification) as the number
of vessels per field; and the result was expressed as a
semi-quantitative scale: +, 0 to 1 vessel/field; ++, 2 to 5
vessels/field; +++, 6 or more vessels/field. Identification
of vessels was achieved using the method specified byWeidner for blood vessels counts: any stained endothelial
cell or cell cluster separated from another microvessel
structure was considered a countable microvessel [25].
Staining with the anti-CC531 antibody allowed count-
ing if the number of individual tumor cells implanted
into the intestinal anastomosis. Counting was performed
in five microscopic fields (×400 magnification) using light
microscopy with microimage software (Olympus, Japan),
and results were expressed as a semi quantitative scale: +,
0 to 5 cells/field; ++, 6 to 10 cells/field; +++, 11 or more
cells/field.
The population of BrdU-positive cells was divided into
mononuclear infiltrating cells and CC531 cells the latter
were recognized by their large, irregular shape. Both pop-
ulations were counted in five microscopic fields (×400
magnification) using light microscopy with microimage
software (Olympus, Japan), and results were expressed as
a semi-quantitative scale: +, 0 to 5 cells/field; ++, 6 to 10
cells/field; +++, 11 or more cells/field.
Deposition of collagen in trichrome stained specimens
was estimated by measuring the thickness of the blue-
stained collagen bundles in the section using light
microscopy with microimage software (Olympus, Japan),
expressed as a semi-quantitative scale: +, 2 μm; ++, 4
μm; +++, 6 μm.
The slides were reviewed independently by three
observers (WLO, MS, and MG). In the event of discrep-
ancies between observers, the slides were reviewed once
again, and results agreed upon by consensus.
Statistics
Results are presented as percentages (mean ± SD). For
statistical analysis the nonparametric Wilcoxon’s rank
sum test and t-test were used. P < 0.05 was considered
significant.
Results
Dehiscence of intestinal anastomosis
In the group of rats with cancer metastases (group 1),
the dehiscence ratio was 50%. There were six cases of
anastomotic dehiscence in total: one each on post-
operative days 2 and 3, and two each on days 5 and 7. In
the group of 12 normal rats (group 2), the dehiscence
ratio was 16.6%, with two cases of anastomotic dehis-
cence in total: one each on post-operative day 2 and 3.
Mononuclear infiltrates of intestinal anastomoses in
cancer-bearing versus normal rats
The mean number per field (×400 magnification) of
mononuclear cells infiltrating the anastomosis in cancer-
bearing versus normal rats, respectively, was as follows:
CD14 cells 33.91 ± 7.58 versus 36.20 ±7.43, MHC II-
positive cells 24.31 ± 7.10 versus 32.25 ± 8.05, and CD3
cells 24.74 ± 6.60 versus 35.84 ± 8.40. There were no
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number of cells per microscopic field or the phenotypes
of mononuclear cells infiltrating the intestinal anasto-
moses (Figure 1A,B).
Blood vessels
In the intestinal anastomotic wounds of cancer-bearing
rats, there were more blood vessels than in normal rats
(17.33 ± 16.48 versus 13.27 ± 11.44, respectively), but this
difference was not statistically significant (P > 0.05). Blood
vessels were counted on slides obtained on post-operative
day 7 and 14 from both normal and cancer-bearing rats
(Figure 2).
BrdU incorporation
There were 18.20 ± 5.39 versus 16.44 ± 4.74 cells/field in
the anastomotic wounds of the cancer-bearing and con-
trol rats, respectively (Figure 3A,B), and this difference
was statistically nonsignificant (P > 0.05). However, stain-
ing of cancer cells for BrdU incorporation showed that
there was a high density of these cells both close to and
at a distance from the suture line. The area occupied by
the CC531 cells reached 5 to 7% of each microscopic field.
However, exact quantitative evaluation was hampered by
the uneven focal distribution of the cells and their
tendency to form glandular structures (Figure 3A).
Connective tissue formation
We did not observe any differences in connective tis-
sue formation or collagen deposition in the intestinal
anastomotic wounds of cancer-bearing versus normal
rats (Figure 4).
CC531 implantation
In 12 out of 12 cancer-bearing rats, CC531 cancer cells
were found in the intestinal anastomotic wound, both at
the edge and the central part of the healing wound. TheFigure 1 Intestinal anastomosis performed in cancer and normal tissu
with anti-ED1-specific antibody for macrophages. Original magnification × 1
cularis mucosa; S, Suture; V, villi.cancer cells in the anastomotic wounds formed clusters
(Figure 5A,B).
Discussion
In the current study we observed two main groups of find-
ings. First, there was no difference between the cancer-
bearing and normal rats in 1) the number or phenotype
of wound-infiltrating mononuclear cells (mainly macro-
phages); 2) the proliferative potential of these wound-
infiltrating mononuclear cells; 3) the connective tissue
formation and collagen deposition within the intestinal
anastomotic wounds; or 4) the neovascularization of
these wounds. Second, we found that: 1) there was mul-
ticenter seeding of cancer cells at the site of the anasto-
moses; 2) cancer cells formed clusters, showing their
ability to proliferate; and 3) BrdU incorporation con-
firmed the high proliferative potential of these cells in
the cancer-bearing group.
Surgical wounding may provide a favorable conditions
for tumor recurrence at the site of anastomosis or in the
abdominal wall [26,27]. The mechanical dissemination
of cancer cells during surgery has been discussed in the
medical literature since the end of the 19th century, and
was extensively studied in the 1960s in animal cancer
models [28]. Attention to this issue was revived by a
number of authors with regard to local recurrences fol-
lowing anterior resections of colon and rectal cancers. In
the majority of instances, the recurrences occurred in
the anastomotic suture line [29-31]. Currently, wound
‘contamination’ by cancer cells at the time of operation
is one of the recognized causes of local recurrence. It
has been suggested that deposition of cancer cells, which
may be desquamating from the tumor surface, persistent
in the peritoneal fluid, or present in circulating blood
and transected lymphatics, may also contribute to some
recurrences [20]. In our study, we found implantation of
CC531 cells in the anastomotic wounds of all the cancer-
bearing rats. There may be two mechanism behind thise. (A) Cancer-colonized tissue, and (B) normal intestinal tissue, stained
00. C, cancer islands; Mo, mononuclear cells (macrophages); Mus, mus-
Figure 2 Newly formed blood vessels in anastomotic wound in
cancer-bearing rat. Similar density of blood vessels was seen in the
normal anastomotic wound. Staining with HIS 52 antibody. Original
magnification × 200. BV, blood vessel.
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the bloodstream may become mechanically trapped in the
wound, and 2) the high cytokine concentration associated
with wound healing may attract cancer cells in other loca-
tions to migrate to the wound and may stimulate cancer
seeding and growth. Robinson and Hoppe showed that V2
rabbit carcinoma injected into the aorta implanted more
frequently in limbs subjected to ischemia or blunt trauma
than in normal limbs [21]. However, this tendency was
not confirmed in the study by Vernick et al., where limbs
were affected by sharp incisional trauma [22].
Disruption of normal tissue structure during tumor
growth activates the host response in a manner similar to
that observed during the normal wound-healing process
described above. Macrophages possess a multitudinous in-
ventory of functions, and are often described as the ‘Swiss
Army knife’ of the immune system. They are recruitedFigure 3 Cancer and mononuclear cells stained for BrdU incorporatio
magnification × 200. C, cancer cells; Mo, mononuclear cells.through the local expression of chemoattractants such as
macrophage colony stimulating factor-1, monocyte chemo-
tactic protein-1, granulocyte/macrophage colony stimulat-
ing factor, macrophage inflammatory protein-1-α, and
macrophage migration inhibitory factor [32-35]. Macro-
phages isolated from different anatomical sites showed
functional and phenotypic differences [36]. Such differ-
ences probably result from the influence of the microenvir-
onment as well as the appropriate activation and nature of
the differentiation stimulus [37,38].
Tumor-associated macrophages (TAMs) are capable of
influencing a number of processes, such as matrix remod-
eling, angiogenesis, and stimulation of tumor growth and
motility, through synthesis of growth and chemotactic fac-
tors [39]. TAMs have potential to carry out both anti-
tumor and pro-tumor activities. There is a hypothesis that
tumors subvert the normal functions of TAMs in order to
promote tumor growth and metastasis [8,38,40,41]. Our
previous studies on the adherence of mononuclear cells
infiltrating CC531 liver tumors revealed a predilection of
CD14 MHC II-positive cells (that is, TAMs) for liver
adenocarcinoma metastases, with the highest propensity
being for adherence to tumor stroma [42]. TAMs and
wound macrophages have functional similarities to one
another; for instance, less cytotoxic activity than activated
macrophages, and have the capacity to affect angiogenesis,
stroma formation, and dissolution [43,44]. Macrophages
contribute to the process of angiogenesis by releasing an-
giogenic factors and secreting factors that stimulate other
cell types, such as fibroblasts and endothelial cells [45].
Angiogenesis is marked by endothelial cell migration
and capillary formation in the proliferative healing phase.
Capillaries supply nutrients for granulation and tissue
deposition. Failure of this process results in lack of heal-
ing. Neovascularization plays a crucial role in successful
wound healing, and is probably regulated by FGF-2 and
VEGF [46]. Fibroblasts play a crucial role in scar tissue
formation during the proliferation, repair, and remodelingn. (A) Cancer colonized and (B) normal anastomosis. Original
Figure 4 Connective tissue formation in the intestinal
anastomosis. The cancer-bearing and normal healing tissues
showed similar features. Trichrome staining, original magnification ×
200. Col, collagen bundles.
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during tumor growth. Fibroblasts produce a number of
growth factors (including FGF, EGF, PDGF, and TGF-β),
and ECM components (such as collagen, elastin and
proteoglycans), which serve in wound and tumor stroma
formation. Fibroblasts also produce matrix metallopro-
teinases and TIMPs, which play crucial roles in remodel-
ing and repair of scar tissue and tumor stroma. It has
been shown that interactions between tumor cells and
normal fibroblasts enhance the invasive and metastatic
potential of the tumor cells [47-49].
Although the presence of cancer at the anastomotic
margin is rarely encountered in modern-day treatment,
as the principles of negative proximal and distal margins
are well appreciated, it is possible that if cancer cells are
present in the distance, they may migrate into the heal-
ing wound, and cause local recurrence. Our study on in-
testinal anastomosis focused on the clinical situation
encountered in patients with disseminated cancer andFigure 5 Seeding of cancer cells forming clusters in the proximity of
magnification (A) × 100; (B) × 200. C, cancer cells; S, suture.nodal and hepatic metastases, after intestinal anasto-
moses performed with apparently ‘clean’ margins. In the
current study, we have a higher dehiscence rate of intes-
tinal anastomoses in the group of cancer-bearing rats
versus normal rats (50% versus 16.6%, respectively). The
early dehiscence rate on days 2 and 3 were equal in both
groups, and were probably associated with technical er-
rors, whereas the late dehiscence in the cancer-bearing
group was probably associated with tumor proliferation
and facilitated by the mechanisms described above. The
most important finding was that the dehiscence rate did
not correlate significantly with the impairment of the heal-
ing process seen in the histologic examinations. There
were no significant differences between the normal and
cancer-bearing rats in either the number or the pheno-
types of the wound-infiltrating cells. In both groups, BrdU
incorporation showed similar proliferative potential for
the wound-infiltrating cells. There were also no signifi-
cant differences between the groups in blood vessel for-
mation or collagen deposition. Histology did not reveal
any differences in the wound-formation process with
the exception of the multicenter seeding of cancer cells
at the site of anastomosis in the cancer-bearing group.
In the intestinal anastomotic wounds, the cancer cells
formed clusters, showing their ability for proliferation.
Additionally BrdU incorporation confirmed the high
proliferative potential of these cells. Similarly to other
reports (Paget’s ‘seed and soil’ hypothesis) [50], we ob-
served preferential growth of tumor cells in the healing
wounds. We hypothesize that the high cytokine concen-
trations generated by the local healing process may
attract cancer cells from distant tissues to migrate to
and proliferate within the wound, and that excessive
production of connective tissue forms a permissive
microenvironment for the growth of colon carcinoma
cells. The growing tumor cells will then stretch the
wound, hampering the process of its contraction and
causing anastomotic dehiscence.the anastomotic wound. Cancer cells are stained red. Original
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Our study particularly applies to the clinical situation
encountered during palliative operations in patients with
disseminated colon cancer. In addition to the technical
contraindications for anastomosis or colostomy in such
patients, the high probability of anastomotic dehiscence
due to cancer wound seeding as shown in our study
should be considered when deciding whether to perform
anastomosis or colostomy in these patients.
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